Fluticasone furoate

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Fluticasone furoate
Fluticasone furoate.svg
Clinical data
AHFS/Drugs.comInternational Drug Names
License data
Pregnancy
category
  • C for Intranasal
Routes of
administration
Intranasal
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability0.51% (Intranasal)
Protein binding91%
MetabolismIntranasal
Hepatic (CYP3A4-mediated)
Elimination half-life15 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.158.130 Edit this at Wikidata
Chemical and physical data
FormulaC27H29F3O6S
Molar mass538.576 g/mol g·mol−1
3D model (JSmol)

Fluticasone furoate is a corticosteroid for the treatment of non-allergic and allergic rhinitis administered by a nasal spray.[1] It is also available as an inhaled corticosteroid to help prevent and control symptoms of asthma. It is derived from cortisol.[2] Unlike fluticasone propionate, which is only approved for children 4 years and older, fluticasone furoate is approved in children as young as 2 years of age when used for allergies. [3]

Brand names[edit]

In the US it is marketed by GlaxoSmithKline for asthma as Arnuity Ellipta and is only available with a prescription.[4] It is marketed over-the-counter for allergic rhinitis as Flonase Sensimist.[5] The Veramyst brand name has been discontinued in the U.S. It is also marketed as Allermist (Japan, アラミスト) and Avamys (Australia, Canada, EU, South Africa, South America, Mexico, Israel, Italy, India and South Korea).

The combination drug fluticasone furoate/vilanterol, marketed as Breo Ellipta (US, Canada) and Relvar Ellipta (UK), is approved for use in the United States for long-term maintenance treatment of airflow obstruction in people with COPD.[6] It is also approved for the treatment of asthma.[7]

See also[edit]

References[edit]

  1. ^ Bruni FM, De Luca G, Venturoli V, Boner AL (2009). "Intranasal corticosteroids and adrenal suppression". Neuroimmunomodulation. 16 (5): 353–62. doi:10.1159/000216193. PMID 19571596.
  2. ^ Kaliner, Michael A. (2011). Rhinitis, An Issue of Immunology and Allergy Clinics - E-Book. Elsevier Health Sciences. ISBN 9781455709328.
  3. ^ https://www.drugs.com/pro/veramyst.html. Missing or empty |title= (help)
  4. ^ https://www.arnuity.com/about-arnuity.html. Missing or empty |title= (help)
  5. ^ https://www.flonase.com/products/childrens-sensimist/. Missing or empty |title= (help)
  6. ^ "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". Food and Drug Administration. May 10, 2013.
  7. ^ "BREO® ELLIPTA® 100/25 (fluticasone furoate 100 mcg and vilanterol 25 mcg inhalation powder)" (PDF).

External Links[edit]